The dog days of summer are here and IPO activity has slowed, but that hasn’t stopped some biotech companies from securing a place in the line leading to Wall Street. Late Friday, SpringWorks Therapeutics and Satsuma Pharmaceuticals filed paperwork to go public.

SpringWorks spun out of Pfizer (NYSE: PFE) nearly two years ago, aiming to acquire drug candidates that stalled within or were shelved by larger pharmaceutical companies. The Stamford, CT, company set its sights on rare diseases and cancer. To start, it
secured the rights to four compounds that no longer fit Pfizer’s strategy.

The most advanced of… Read more »